Recent Updates
Recently added Catalysts
MDGL Positive Sentiment

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Monday, December 15, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Madrigal Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be accessible via a live broadcast, with a replay available afterward. The company focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its drug Rezdiffra being the first FDA-approved therapy for this condition.
Price reaction · baseline $560.55 (2025-12-15 close) · hit after-hours · 1 other MDGL headline(s) in the window, move may be shared
day 0 close · peak
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal Pharmaceuticals is participating in a prestigious healthcare conference.
  • The company is focused on addressing a significant unmet medical need.
  • Rezdiffra is the first approved medication for MASH with moderate to advanced fibrosis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+125%
120-day peak, hindsight
Typical move
4.2%
average across 7 past catalysts
Cash runway
~45 mo
Minimal dilution risk
Lead asset
Resmetirom
Phase 3 · Non-Alcoholic Fatty Liver Disease

Full Press Release Details

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST.
The presentation will be broadcast live and can be accessedhereor by visiting Madrigal’s Investor Relations Events and Presentationspage. A replay of the webcast will be available after the event.
About MadrigalMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visitwww.madrigalpharma.com.

Investor ContactTina Ventura,IR@madrigalpharma.com

Media ContactChristopher Frates,media@madrigalpharma.com

Frequently Asked Questions

When will Madrigal present at the J.P. Morgan Conference?

Madrigal Pharmaceuticals will present on January 12, 2026, at 1:30 PM PST.

How can I access the presentation?

The presentation will be broadcast live and available on Madrigal's Investor Relations page.

What is Rezdiffra used for?

Rezdiffra is approved for treating metabolic dysfunction-associated steatohepatitis (MASH).

Is Rezdiffra the first treatment for MASH?

Yes, Rezdiffra is the first FDA-approved medication for MASH with moderate to advanced fibrosis.

ShareAdd on Google
Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals J.P. Morgan Conference Rezdiffra MASH
Last updated: Dec 15, 2025

Biotech snapshot

Cash runway
$839M liquidity · $19M/mo burn
~45 mo
Minimal dilution risk
Lead asset
ResmetiromPhase 3
Non-Alcoholic Fatty Liver Disease →

Catalyst track record

+125%
best trade around MDGL's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for MDGL.

See every catalyst's timing & PoA →